Free Trial
NASDAQ:OGI

Organigram Global Q3 2025 Earnings Report

Organigram Global logo
$1.43 -0.05 (-3.38%)
Closing price 04:00 PM Eastern
Extended Trading
$1.42 0.00 (-0.35%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organigram Global EPS Results

Actual EPS
N/A
Consensus EPS
-$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

Organigram Global Revenue Results

Actual Revenue
N/A
Expected Revenue
$68.04 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Organigram Global Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Organigram Global Earnings Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
OGI Organigram Global Inc. - Seeking Alpha
See More Organigram Global Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organigram Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organigram Global and other key companies, straight to your email.

About Organigram Global

Organigram Global (NASDAQ:OGI) (NASDAQ: OGI) is a Canadian licensed producer of cannabis and cannabis-derived products headquartered in Moncton, New Brunswick. Founded in 2013, the company has established a portfolio that spans dried flower, pre-rolls, oils, edibles, and concentrates for both medical and adult-use markets. Organigram operates state-of-the-art indoor and hybrid greenhouse cultivation facilities, which utilize advanced lighting and climate control technologies to optimize yield consistency and product quality.

Since commencing commercial production in 2015, Organigram has focused on expanding its product lines and production capacity. The company’s premium brands, including Organigram, Edison Cannabis Co., and Trailblazer, address diverse consumer preferences across potency levels, formats, and price points. Organigram’s SunSet Farms greenhouse, launched in 2020, added significant square footage to its cultivation footprint, enabling the company to supply wholesalers and retailers coast-to-coast in Canada.

Beyond its domestic footprint, Organigram has pursued international opportunities under Good Manufacturing Practice (GMP) certification, targeting medicinal markets in Europe and other regulated jurisdictions. Memoranda of understanding and supply agreements with overseas distributors have positioned the company to export pharmaceutical-grade cannabis products once regulatory approvals are secured. Organigram also invests in research and development initiatives aimed at novel cannabinoid formulations and delivery systems.

Organigram’s leadership team is led by CEO Greg Engel, who has brought over two decades of consumer goods and cannabis industry experience to the organization. Supporting him are President and COO Lisa Campbell, CFO Eric McClure, and Chief Science Officer Dr. Robert Myers, each overseeing key operational, financial, and scientific functions. The board of directors comprises industry veterans and former government officials who guide corporate governance, strategic direction, and risk management practices.

View Organigram Global Profile

More Earnings Resources from MarketBeat